Please check your internet connection and try again.
# Dexamethasone in Chronic ITP
## Overview
Dexamethasone is a potent synthetic glucocorticoid with minimal mineralocorticoid activity. It is frequently utilized in Immune Thrombocytopenia (ITP) as "pulse" therapy to induce rapid increases in platelet counts, often preferred over continuous lower-dose prednisone due to potentially higher response rates and shorter duration of exposure.
## Primary Indications
* First-line induction therapy for newly diagnosed or relapsed/refractory symptomatic ITP.
* Preoperative management for patients with ITP requiring surgery.
## Adult Dosing
* **Standard Regimen:** 40 mg orally once daily for 4 consecutive days.
* **Cycles:** May be repeated every 14–28 days depending on initial platelet response and institutional protocols.
* **Rescue:** Repeat cycles may be administered based on platelet count nadirs.
## Pediatric Dosing
* **Standard Regimen:** 40 mg/m²/day (maximum 40 mg/dose) orally for 4 consecutive days.
* Dosing is typically administered in periodic cycles (e.g., every 28 days) based on clinical response.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be decreased; dosage reduction may be necessary in patients with severe hepatic impairment.
* **Renal Impairment:** No standard adjustment required; however, monitor for fluid retention.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or any component of the formulation.
* Avoid administration of live or attenuated vaccines in patients receiving immunosuppressive doses.
## Adverse Effects
* **Common:** Insomnia, hyperglycemia, emotional lability, increased appetite, weight gain, dyspepsia, and acne.
* **Serious:** Increased risk of infection, GI ulceration/bleeding, hypertension, fluid retention, aseptic necrosis of bone (usually with chronic use), and psychiatric disturbances (e.g., psychosis, depression).
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, phenobarbital, rifampin) may decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, clarithromycin, ritonavir) may increase dexamethasone toxicity.
* **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding.
* **Antidiabetic agents:** Glucocorticoids antagonize hypoglycemic effects; increased monitoring of blood glucose is required.
## Monitoring
* **Baseline:** CBC with differential, blood glucose, blood pressure, and mental status.
* **During Treatment:** Daily blood glucose (especially in patients with history of diabetes), blood pressure, and serial platelet counts to assess response (typically 7–14 days post-cycle).
* **Long-term/Repeated cycles:** Bone density monitoring and screening for cataracts/glaucoma.
## Clinical Pearls
* **Efficacy:** High-dose pulse dexamethasone has shown superior sustained response rates compared to standard-dose prednisone in many clinical studies and guidelines (e.g., ASH guidelines).
* **Administration:** Take with food or milk to minimize gastric irritation. Administering in the morning helps mitigate insomnia.
* **Tapering:** While the 4-day pulse regimen typically does not require a formal taper, patients on prolonged courses or those transitioning between therapies must be evaluated for adrenal insufficiency.
* **Variability:** Protocols vary by institution regarding the number of "pulses" allowed; consult local hematology guidelines for specific rescue therapy intervals.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines change frequently. Always verify current prescribing information, institutional protocols, and patient-specific factors via official drug resources (e.g., Lexicomp, UpToDate, or the manufacturer’s package insert) before prescribing or administering medication.*
